NeuroScientific Biopharmaceuticals (ASX:NSB) has reported encouraging results from two early studies of its StemSmart mesenchymal stromal cell (MSC) therapy in renal transplantation, reinforcing its potential to improve outcomes for patients facing the risks of graft rejection and transplant-related complications. …
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
It is profoundly wrong for any system to exclude compassion while outsourcing it to others
March 16, 2026 - - Latest News -
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 - - Latest News -
GSK claims Pharma Cup as Kosi Challenge surpasses fundraising record
March 15, 2026 - - Latest News -
New program aims to make women’s health care more affordable and accessible
March 13, 2026 - - Latest News -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News